Nasdaq

Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer

Approval reinforces Myriad’s leadership in comprehensive HRD testing and establishes MyChoice CDx as the only FDA-approved companion diagnostic for Zejula in the United States SALT LAKE CITY, March 17 ...
Business Insider

Myriad Launches riskScore™ Beginning the Next Epoch in Hereditary Cancer TestingProvides Individualized Breast Cancer Risk for Patients Testing Negative with the myRisk ...

SALT LAKE CITY, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that it has launched riskScore ™, a ...
Nasdaq

Myriad Genetics Unveils Promising Clinical Data on Precise MRD Test for Oligometastatic Clear-Cell Renal Cell Carcinoma at AACR Annual Meeting

Myriad Genetics will present new data on its Precise MRD test for renal cell carcinoma at the AACR Annual Meeting. Myriad Genetics, Inc. announced that it will present new clinical data on its Precise ...